The Evaluation of Cardiovascular Risk in Diabetic Patients

[1] ADA. Standards of Medical Care in Diabetes - 2021 Abridged for Primary Care Providers. Clinical Diabetes. 2021;39:14–43. ADA Standards of Medical Care in Diabetes - 2021 Abridged for Primary Care Providers Clinical Diabetes 2021 39 14 43 10.2337/cd21-as01783961333551551 Search in Google Scholar

[2] ADA. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S73–S85 ADA Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018 Diabetes Care 2018 41 Suppl 1 S73 S85 10.2337/dc18-S00829222379 Search in Google Scholar

[3] Almeda-Valdes P, Cuevas-Ramos D, Mehta R, Gomez-Perez FJ, Aguilar-Salinas CA. UKPDS Risk Engine, decode and diabetes PHD models for the estimation of cardiovascular risk in patients with diabetes. Curr Diabetes Rev. 2010;6:1–8. Almeda-ValdesP Cuevas-RamosD MehtaR Gomez-PerezFJ Aguilar-SalinasCA UKPDS Risk Engine, decode and diabetes PHD models for the estimation of cardiovascular risk in patients with diabetes Curr Diabetes Rev 2010 6 1 8 10.2174/15733991079044264620034373 Search in Google Scholar

[4] Bell, D. Diabetes therapy and cardiac risk. Cleveland Clinic Journal of Medicine. 2015;82(3):140 BellD Diabetes therapy and cardiac risk Cleveland Clinic Journal of Medicine 2015 82 3 140 10.3949/ccjm.82c.0300125932734 Search in Google Scholar

[5] Bittencourt MS & Hajjar LA. Insulin therapy in insulin resistance: Could it be part of a lethal pathway? Atherosclerosis. 2015;240(2):400–401 BittencourtMS HajjarLA Insulin therapy in insulin resistance: Could it be part of a lethal pathway? Atherosclerosis 2015 240 2 400 401 10.1016/j.atherosclerosis.2015.04.01325890058 Search in Google Scholar

[6] Campesi I, Franconi F, Seghieri G, Meloni M.. Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes. Pharmacological Research. 2017:119:195–207 CampesiI FranconiF SeghieriG MeloniM Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes Pharmacological Research 2017 119 195 207 10.1016/j.phrs.2017.01.02328189784 Search in Google Scholar

[7] Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288–98 Control Group TurnbullFM AbrairaC AndersonRJ ByingtonRP ChalmersJP Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 2009 52 2288 98 10.1007/s00125-009-1470-019655124 Search in Google Scholar

[8] Currie CJ & Johnson JA.. The safety profile of exogenous insulin in people with type 2 diabetes: Justification for concern. Diabetes, Obesity and Metabolism. 2012:14(1):1–4 CurrieCJ JohnsonJA The safety profile of exogenous insulin in people with type 2 diabetes: Justification for concern Diabetes, Obesity and Metabolism 2012 14 1 1 4 10.1111/j.1463-1326.2011.01469.x21736688 Search in Google Scholar

[9] Davidson JA. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: Overview of current evidence. Postgraduate Medicine, 2019;131(4):251–260 DavidsonJA SGLT2 inhibitors in patients with type 2 diabetes and renal disease: Overview of current evidence Postgraduate Medicine 2019 131 4 251 260 10.1080/00325481.2019.160140430929540 Search in Google Scholar

[10] Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701 DaviesMJ D’AlessioDA FradkinJ KernanWN MathieuC MingroneG Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2018 41 2669 701 10.2337/dci18-0033624520830291106 Search in Google Scholar

[11] European Medicines Agency. https://www.ema.europa.eu/en European Medicines Agency https://www.ema.europa.eu/en Search in Google Scholar

[12] Fadini GP., Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: Data from the FDA Adverse Event Reporting System. Diabetologia, 2017;60(8):1385–1389 FadiniGP. BonoraBM AvogaroA SGLT2 inhibitors and diabetic ketoacidosis: Data from the FDA Adverse Event Reporting System Diabetologia 2017 60 8 1385 1389 10.1007/s00125-017-4301-828500396 Search in Google Scholar

[13] Fei Y, Tsoi MF, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: A network meta-analysis. Cardiovascular Diabetology. 2019:18(1):112 FeiY TsoiMF CheungBMY Cardiovascular outcomes in trials of new antidiabetic drug classes: A network meta-analysis Cardiovascular Diabetology 2019 18 1 112 10.1186/s12933-019-0916-z671438331462224 Search in Google Scholar

[14] Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014;129:e28–292 GoAS MozaffarianD RogerVL BenjaminEJ BerryJD BlahaMJ Heart disease and stroke statistics--2014 update: a report from the American Heart Association Circulation 2014 129 e28 292 10.1161/01.cir.0000441139.02102.80540815924352519 Search in Google Scholar

[15] Herman ME, O’Keefe JH, Bell DSH, Schwartz SS.. Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. Progress in Cardiovascular Diseases. 2017:60(3):422–434 https://doi.org/10.1016/j.pcad.2017.09.001 HermanME O’KeefeJH BellDSH SchwartzSS Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes Progress in Cardiovascular Diseases 2017 60 3 422 434 https://doi.org/10.1016/j.pcad.2017.09.001 10.1016/j.pcad.2017.09.00128958751 Search in Google Scholar

[16] Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89. HolmanRR PaulSK BethelMA MatthewsDR NeilHAW 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008 359 1577 89 10.1056/NEJMoa080647018784090 Search in Google Scholar

[17] Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96. InzucchiSE BergenstalRM BuseJB DiamantM FerranniniE NauckM Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 2012 55 1577 96 10.1007/s00125-012-2534-022526604 Search in Google Scholar

[18] Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. Journal of Diabetes and Its Complications. 2013;27(5):479–484 JohnssonKM PtaszynskaA SchmitzB SuggJ ParikhSJ ListJF Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin Journal of Diabetes and Its Complications 2013 27 5 479 484 10.1016/j.jdiacomp.2013.04.01223806570 Search in Google Scholar

[19] Kashiwagi A, Maegawa H. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardiorenal protection in the treatment of patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. 2017;8(4):416–427 KashiwagiA MaegawaH Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardiorenal protection in the treatment of patients with type 2 diabetes mellitus Journal of Diabetes Investigation 2017 8 4 416 427 10.1111/jdi.12644549703728178390 Search in Google Scholar

[20] Kautzky-Willer A, Harreiter J, Abrahamian H, Weitgasser R, Fasching P, Hoppichler F, et al. Sex and gender-specific aspects in prediabetes and diabetes mellitus-clinical recommendations. Wien Klin Wochenschr. 2019;131:221–8. Kautzky-WillerA HarreiterJ AbrahamianH WeitgasserR FaschingP HoppichlerF Sex and gender-specific aspects in prediabetes and diabetes mellitus-clinical recommendations Wien Klin Wochenschr 2019 131 221 8 10.1007/s00508-018-1421-130980153 Search in Google Scholar

[21] Kautzky-Willer A, Harreiter J. Sex and gender differences in therapy of type 2 diabetes. Diabetes Research and Clinical Practice. 2017;131:230–241 Kautzky-WillerA HarreiterJ Sex and gender differences in therapy of type 2 diabetes Diabetes Research and Clinical Practice 2017 131 230 241 10.1016/j.diabres.2017.07.01228779681 Search in Google Scholar

[22] Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocrine Reviews. 2016;37(3):278–316 Kautzky-WillerA HarreiterJ PaciniG Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus Endocrine Reviews 2016 37 3 278 316 10.1210/er.2015-1137489026727159875 Search in Google Scholar

[23] Kautzky-Willer A, von Euler M, Oertelt-Prigione S. Editorial: Sex and Gender Aspects in Diabetes. Frontiers in Endocrinology. 2019;10:813 Kautzky-WillerA von EulerM Oertelt-PrigioneS Editorial: Sex and Gender Aspects in Diabetes Frontiers in Endocrinology 2019 10 813 10.3389/fendo.2019.00813697759532010058 Search in Google Scholar

[24] Kavaric N, Klisic A, Ninic A. Cardiovascular Risk Estimated by UKPDS Risk Engine Algorithm in Diabetes. Open Med (Wars). 2018;13:610–7. KavaricN KlisicA NinicA Cardiovascular Risk Estimated by UKPDS Risk Engine Algorithm in Diabetes Open Med (Wars) 2018 13 610 7 10.1515/med-2018-0086640014730847393 Search in Google Scholar

[25] Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002;33:1776–81. KothariV StevensRJ AdlerAI StrattonIM ManleySE NeilHA UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine Stroke 2002 33 1776 81 10.1161/01.STR.0000020091.07144.C712105351 Search in Google Scholar

[26] Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5:444–70. Martín-TimónI Sevillano-CollantesC Segura-GalindoA del Cañizo-GómezFJ Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes 2014 5 444 70 10.4239/wjd.v5.i4.444412758125126392 Search in Google Scholar

[27] Palmer SC, Tendal B, Mustafa RA, et. al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. BMJ (Clinical Research Ed.). 2021;372:m4573 PalmerSC TendalB MustafaRA Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials BMJ (Clinical Research Ed.) 2021 372 m4573 10.1136/bmj.m4573780489033441402 Search in Google Scholar

[28] Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. Int J Endocrinol Metab. 2019;17. RabizadehS NakhjavaniM EsteghamatiA Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review Int J Endocrinol Metab 2019 17 10.5812/ijem.84353662861631372172 Search in Google Scholar

[29] Riddle MC, Ambrosius WT, Brillon DJ et al. (ACCORD) Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial. Diabetes Care. 2010;33(5):983–990 RiddleMC AmbrosiusWT BrillonDJ (ACCORD) Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial Diabetes Care 2010 33 5 983 990 10.2337/dc09-1278285820220427682 Search in Google Scholar

[30] Santilli F, D’Ardes D, Guagnano MT, Davi G. Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach. Curr Med Chem. 2017;24:2602–27. SantilliF D’ArdesD GuagnanoMT DaviG Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach Curr Med Chem 2017 24 2602 27 10.2174/092986732466617071012114528699503 Search in Google Scholar

[31] Savarese G, Perrone-Filardi P, D’Amore C, Vitale C, Trimarco B, Pani L, et al. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. International Journal of Cardiology. 2015;181:239–44. SavareseG Perrone-FilardiP D’AmoreC VitaleC TrimarcoB PaniL Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis International Journal of Cardiology 2015 181 239 44 10.1016/j.ijcard.2014.12.01725528528 Search in Google Scholar

[32] Seghieri G, Policardo L, Anichini R, Franconi F, Campesi I, Cherchi S, Tonolo G. The Effect of Sex and Gender on Diabetic Complications. Current Diabetes Reviews. 2017;13(2):148–160 SeghieriG PolicardoL AnichiniR FranconiF CampesiI CherchiS TonoloG The Effect of Sex and Gender on Diabetic Complications Current Diabetes Reviews 2017 13 2 148 160 10.2174/1573399812666160517115756 Search in Google Scholar

[33] Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents. Circulation Research. 2018;122(10): 1439–1459 ScheenAJ Cardiovascular Effects of New Oral Glucose-Lowering Agents Circulation Research 2018 122 10 1439 1459 10.1161/CIRCRESAHA.117.311588 Search in Google Scholar

[34] Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671–9. StevensRJ KothariV AdlerAI StrattonIM United Kingdom Prospective Diabetes Study (UKPDS) Group The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56) Clin Sci (Lond) 2001 101 671 9 10.1042/CS20000335 Search in Google Scholar

[35] UKPDS group. (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. 352(9131):854–865 UKPDS group 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) The Lancet 352 9131 854 865 10.1016/S0140-6736(98)07037-8 Search in Google Scholar

[36] UKPDS. UKPDS Risk Engine: Overview https://www.dtu.ox.ac.uk/riskengine/ UKPDS UKPDS Risk Engine: Overview https://www.dtu.ox.ac.uk/riskengine/ Search in Google Scholar

[37] Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215–225 VallonV ThomsonSC Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition Diabetologia 2017 60 2 215 225 10.1007/s00125-016-4157-3 Search in Google Scholar

[38] Wang H, Ba Y, Cai R-C, Xing Q. Association between diabetes mellitus and the risk for major cardiovascular outcomes and all-cause mortality in women compared with men: a meta-analysis of prospective cohort studies. BMJ Open. 2019;9:e024935. WangH BaY CaiR-C XingQ Association between diabetes mellitus and the risk for major cardiovascular outcomes and all-cause mortality in women compared with men: a meta-analysis of prospective cohort studies BMJ Open 2019 9 e024935 10.1136/bmjopen-2018-024935 Search in Google Scholar

[39] Xu J, Rajaratnam R. Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes. Cardiovascular Diabetology. 2017;16:18. XuJ RajaratnamR Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes Cardiovascular Diabetology 2017 16 18 10.1186/s12933-017-0499-5 Search in Google Scholar

[40] Yang L, Fish AF, Zhu Y, Yuan X, Li J, Wang X, et al. Sex differences in 10-year ischemic cardiovascular disease risk prediction in Chinese patients with prediabetes and type 2 diabetes. BMC Cardiovascular Disorders. 2019;19:301. YangL FishAF ZhuY YuanX LiJ WangX Sex differences in 10-year ischemic cardiovascular disease risk prediction in Chinese patients with prediabetes and type 2 diabetes BMC Cardiovascular Disorders 2019 19 301 10.1186/s12872-019-1232-y Search in Google Scholar

[41] Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–9. ZelnikerTA WiviottSD RazI ImK GoodrichEL BonacaMP SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Lancet 2019 393 31 9 10.1016/S0140-6736(18)32590-X Search in Google Scholar

[42] Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA. 2018;319(15):1580–1591 ZhengSL RoddickAJ Aghar-JaffarR Shun-ShinMJ FrancisD OliverN MeeranK Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis JAMA 2018 319 15 1580 1591 10.1001/jama.2018.3024593333029677303 Search in Google Scholar

[43] Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2015;373:2117–28 ZinmanB WannerC LachinJM FitchettD BluhmkiE HantelS Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes New England Journal of Medicine 2015 373 2117 28 10.1056/NEJMoa150472026378978 Search in Google Scholar